Considerable variety in how patients respond to treatments, driven by differences in their
geno-and/or phenotypes, calls for a more tailored approach. This is already happening, and …

Parasites and pathogens are a fundamental driving force in the ecology and evolution of
mammalian populations, and understanding disease processes in natural populations is an …

Drug development expenditures continue to escalate, in part reflecting inefficiencies in
current drug discovery paradigms. Traditional drug discovery has been dichotomous …

There are considerable differences in how patients respond to treatments due to a number
of factors calling for personalised approaches to care, which is happening. However, the …

3.3. 1 Éxito regulatorio, tiempos de evaluación, extensiones 132 3.3. 2 Metodología y
evidencia clínica de ensayos de registro 138 3.3. 3 Indicaciones: población, biomarcador …

Biomarkers have been an important part of clinical trials for decades. The recent surge of
interest in biomarkers is due to advances in knowledge of molecular pathways and …